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Abbreviations
ACEI  Angiotensin converting enzyme inhibitor
AKI  Acute kidney injury
ARB  Angiotensin receptor blocker
BMI  Body mass index
BP  Blood pressure
CCB  Calcium channel blocker
CKD  Chronic kidney disease
CVD  Cardiovascular disease
eGFR  Estimated glomerular filtration rate
ESKD  End-stage kidney disease
MRB  Mineralocorticoid receptor blocker
QOL  Quality of life
RAS  Renin angiotensin system
Levels of evidence
A High: We are confident that the true effect lies close to that 
of the estimate of the effect.
B Moderate: The true effect is likely to be close to the 
estimate of the effect, but there is a possibility that it is sub-
stantially different.
C Low: The true effect may be substantially different 
from the estimate of the effect.
D Very low: The estimate of the effect is very uncertain 
and might often be far from the true effect.
None
Grade of recommendation
1 “We recommend”
2 “We suggest”
None
Chapter 1. Diagnosis and definition 
of chronic kidney disease
CQ1-1: How can we diagnose CKD?
Statement: CKD is defined as the presence of either of the 
conditions listed below lasting for more than 3 months. 
(Level: None, Grade: 1)
(1) Findings suggesting kidney damage, i.e., abnormal 
findings in blood or urinary tests, imaging studies or 
pathological evaluations. In particular, evidence of 
proteinuria ≥ 0.15 g/gCr (albuminuria ≥ 30 mg/gCr) is 
important.
(2) GFR < 60 mL/min/1.73 m2
In clinical practice, eGFR is calculated by the following 
GFR equation adjusted for the Japanese:
eGFR (mL/min/1.73 m2) = 194 x  Cr-1.094 x  Age-0.287 (x 
0.739 if female)
Note: We recommend that serum creatinine (Cr) value 
(mg/dL) should be evaluated by the enzymatic assay method 
and rounded off to 2 decimal places. The Japanese GFR 
equation is applicable to adults aged 18 years or older.
CQ 1–2: How can we evaluate the severity of CKD?
Statement: We recommend that CKD severity should be 
evaluated by cause, GFR category, and degree of proteinuria/
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albuminuria based on the CGA classification. (Level: A, 
Grade: 1)
CQ 2: Should routine health check-up patients with dip-
stick proteinuria (1+ or greater) be referred for clinic 
consultation?
Statement: In health check-up subjects, dipstick proteinuria 
(1 + or greater) is a significant risk factor not only for ESKD 
but also for CVD and all-cause mortality. We recommend 
that health check-up subjects with dipstick proteinuria (1+ 
or greater) consult a specialized clinic, because these risks 
could be decreased by adequate treatment. (Level: C, Grade: 
1)
CQ 3: Should the elderly (aged ≥ 65 years) routine health 
check-up subjects with an eGFR < 45, be recommended to 
visit the clinic?
Should routine health check-up patients with dipstick pro-
teinuria (1+ or greater) be referred for clinic consultation?
Statement: Even among the elderly, aged ≥ 65 years, the 
risks of all-cause mortality and ESKD risks increased in 
those with an eGFR level < 45. Thus, we recommend that 
elderly CKD patients with an eGFR level of less than 45 
should visit the clinic. (Level: B, Grade: 1)
CQ 4: Is examination of proteinuria/albuminuria recom-
mended in the Specific Health Check-ups and Guidance 
Programs in Japan?
Statement: Examination of proteinuria/albuminuria is rec-
ommended in the Specific Health Check-ups and Guidance 
Program in Japan, because proteinuria/albuminuria is associ-
ated with increased risks of all-cause mortality, CVD onset, 
and renal impairment. (Level: C, Grade: 1)
Chapter 2. Modification of life‑style
Q1: Is smoking cessation recommended for people with 
CKD?
Statement: We recommend that individuals with CKD stop 
smoking to reduce progression of CKD and risk of all-cause 
mortality. (Level: B, Grade: 1)
CQ2: How much alcohol is safe for patients with CKD?
Statement: There is insufficient evidence to recommend an 
adequate amount of alcohol to adults with CKD. (Level: D, 
Grade: None)
CQ3: Are treatments for sleep apnea syndrome (SAS) rec-
ommended for patients with CKD?
Statement: We suggest that CKD patients with SAS undergo 
medical treatment. (Level: D, Grade: 2)
CQ4: Are pneumococcal and influenza vaccination recom-
mended for patients with CKD?
Statement: We suggest that patients with CKD should be 
vaccinated because both vaccines induce higher titers of 
antibodies. Clinical benefits of these vaccines in preventing 
infections remains to be elucidated. (Level: C, Grade: 2)
Chapter 3. Management of diet
CQ1: Is the intervention of a registered dietitian recom-
mended for CKD patient treatment?
Statement: We recommend intervention of registered die-
titian with specific training on medical guidance of CKD 
patients to prevent the progression of CKD stages. (Level: 
C, Grade: 1)
CQ2: Is dietary protein restriction recommended to prevent 
the progression of CKD?
Statement: We recommend individualized protein restriction 
for patients with CKD in accordance with their specific clini-
cal condition, in addition to nutrition guidance consisting 
of a low protein diet under the management of the medical 
team with nephrologists and registered dietitians. (Level: 
B, Grade: 1)
CQ3: Should serum potassium of patients with CKD be cor-
rected for the reduction of mortality and CVD?
Statement: We suggest that serum potassium levels should 
be maintained between 4.0 and 5.4 mEq/L for the reduc-
tion of mortality and CVD in patients with CKD. (Level: 
C, Grade: 2)
CQ4: Is it recommended to restrict salt intake between 3 and 
6 g/day for better prognosis of CKD patients?
Statement: We recommend restricting salt intake to below 
6 g/day to prevent hypertension, proteinuria, and CVD. It 
is recommended to set a lower limit for each patient with 
3 g/day as a guide because extreme salt restriction could be 
harmful. (Level: C, Grade: 1)
3Clinical and Experimental Nephrology (2019) 23:1–15 
1 3
CQ5: Is it recommended to treat metabolic acidosis of CKD 
patients to prevent deterioration of renal function?
Statement: We recommend treating metabolic acidosis with 
sodium bicarbonate and other such bases to prevent hyper-
tension, proteinuria, and CVD. It is recommended to con-
sider treatment when a patient’s  HCO3- is below 21 mmol/L. 
(Level: B, Grade: 1)
Chapter 4. Management of hypertension 
and cardiovascular disease
CQ1: Could appropriate BP control prevent the incidence of 
CKD in hypertensive patients?
Statement: There is substantial supportive evidence indicat-
ing a positive association between high BP and development 
of incident CKD. Management of hypertension is strongly 
recommended for the prevention of CKD. Treatment to con-
trol excessive BP variations, such as nocturnal hyperten-
sion or morning surge, might be more beneficial. (Level: 
C, Grade: 1)
CQ2: Is a target BP < 130/80 mmHg recommended for CKD 
patients (< 75 years of age) associated with hypertension?
Statement:
<CKD stage G1, 2>
A target BP < 130/80 mmHg is recommended for adults 
with hypertension and CKD associated with diabetes. 
(Level: B, Grade: 1)
A target BP < 140/90 mmHg is recommended for adults 
with hypertension and CKD with A1 level proteinuria not 
associated with diabetes. (Level: A, Grade: 1)
A target BP < 130/80 mmHg is recommended for adults 
with hypertension and CKD with A2 or A3 level proteinuria 
not associated with diabetes. (Level: C, Grade: 1)
<CKD stage G3–5>
A target BP < 130/80 mmHg is recommended for adults 
with hypertension and CKD associated with diabetes. 
(Level: C, Grade: 2)
A target BP < 140/90 mmHg is recommended for adults 
with hypertension and CKD with A1 level proteinuria not 
associated with diabetes. (Level: C, Grade: 2)
A target BP < 130/80 mmHg is recommended for adults 
with hypertension and CKD with A2 or A3 level proteinuria 
not associated with diabetes. (Level: C, Grade: 2)
A systolic BP suppression below 110 mmHg is not recom-
mended for adults with hypertension and CKD, regardless 
of CKD stage. (Level: C, Grade: 2)
CQ3: Is a target BP < 150/90 mmHg recommended for 
elderly CKD patients (aged ≥ 75 years old) associated with 
hypertension?
Statement:
<CKD stage G1, 2>
A target BP < 150/90  mmHg is recommended for 
elderly patients with hypertension and CKD. (Level: C, 
Grade: 1)
A target BP < 140/90  mmHg is recommended for 
elderly patients with hypertension and CKD who may tol-
erate treatment with antihypertensive agents without any 
adverse events. (Level: C, Grade: 1)
<CKD stage 3–5>
Recommendations are the same as those for CKD stage 
G1, 2. (Level: C, Grade: 2)
Systolic BP suppression below 110 mmHg is not rec-
ommended for elderly patients with hypertension and 
CKD, regardless of the CKD stage. (Level: C, Grade: 2)
CQ4: What is the appropriate antihypertensive agent for 
CKD patients associated with hypertension?
Statement:
In CKD patients with diabetes mellitus (A1–A3 cat-
egory) and without diabetes mellitus (A2, 3 category), 
ACEIs or ARBs are recommended. (Level: B, Grade: 1)
In CKD patients without diabetes (A1 category), 
ACEIs, ARBs, CCBs or thiazide diuretics are recom-
mended. (Level: B, Grade: 1)
In CKD stages G4, 5, CCBs are recommended if ACEIs 
or ARBs may not be tolerated, despite dose-reduction, due 
to worsening of renal function or hyperkalemia. (Level: 
C, Grade: 1)
In CKD stages G4, 5 in elderly patients aged more 
than 75 years, initial therapy should be CCBs because 
RAS inhibitors could deteriorate renal function in elderly 
patients due to dehydration or ischemia. (Level: C, Grade: 
1)
CQ5: What are the appropriate antihypertensive agents for 
adults with CKD and CVD?
Statement: Recommended antihypertensive agents and 
the evidence levels of their prescriptions depend on the cat-
egories of CVD and the stage of CKD without stage 5D and 
transplantation.
<CKD stage G1-3a>
[Coronary artery disease (CAD)]
Initial antihypertensive therapy should be ACEIs, beta-
blockers, or ARBs. (Level: A, Grade: 1)
[Heart failure with reduced ejection fraction (HFrEF)]
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ACEIs, beta-blockers, MRBs, or ARBs are recom-
mended as the preferred antihypertensive agents in patients 
with CKD and HFrEF. (Level: A, Grade: 1)
[Heart failure with preserved ejection fraction (HFpEF)]
Initial antihypertensive therapy might consist of beta-
blockers, ACEIs, ARBs, or MRBs. (Level: C, Grade: 2)
[Volume overload]
Initial antihypertensive therapy might consist of diuret-
ics. (Level: D, Grade: None)
[Stroke (chronic phase), Peripheral artery diseases]
Appropriate initial antihypertensive agents could not be 
recommended. (Level: D, Grade: None)
<CKD Stage G3b-5 without G5D and transplantation>
[Coronary artery disease (CAD)]
Initial antihypertensive therapy should be ACEIs, beta-
blockers, or ARBs. (Level: C, Grade: 2) (Table 1)
[Heart failure (HFrEF)]
ACEIs or ARBs are recommended as the preferred 
antihypertensive agents in patients with CKD and HFrEF. 
(Level: D, Grade: 2) (Table 2)
[Heart failure (HFpEF)]
Initial antihypertensive therapy may consist of ACEIs 
or ARBs. (Level: D, Grade: 2)
[Volume overload]
Initial antihypertensive therapy may consist of diuret-
ics. (Level: D, Grade: None)
[Stroke (chronic phase), Peripheral artery diseases]
Appropriate initial antihypertensive reagents could not be 
recommended. (Level: D, Grade: None)
In CKD patients stage G3b-5 (without 5D and transplant), 
antihypertensive therapy with ACEIs or ARBs might be 
intolerable due to hyperkalemia or renal impairment. The 
initial dose of ACEIs or ARBs should be low and gradually 
titrated upward as needed. (Level: D, Grade: None)
Chapter 5. Management of nephrosclerosis 
and renal artery stenosis
CQ1: Is strict reduction of BP recommended for CKD 
caused by nephrosclerosis with hypertension?
Statement: We do not suggest the strict reduction of BP to a 
systolic pressure of < 120 mmHg in CKD caused by nephro-
sclerosis with hypertension, especially in A1 category pro-
teinuria due to the risk of AKI. We suggest a target level of 
< 140/90 mmHg. (Level: C, Grade: 2)
CQ2: Which antihypertensive drugs are recommended for 
CKD with renal artery stenosis?
Statement: We suggest the use of RAS inhibitor for CKD 
with unilateral renal artery stenosis because it is supe-
rior in reducing BP in such patients compared to other 
Table 1  In case of CKD with coronary artery disease
Table 2  In case of CKD with heart failure (HFrEF)
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antihypertensive drugs and may suppress progression to 
mortality, onset of CVD and progression of renal dysfunc-
tion. However, to avoid the risk of AKI, it is necessary to 
adjust the dose carefully starting with a low dose and check-
ing the serum Cr and K levels approximately 2 weeks after 
start. A RAS inhibitor is not used in principle when bilateral 
renal artery stenosis is suspected. (Level: C, Grade: 2)
CQ3: Which imaging studies are recommended for CKD 
(Stage G1-3) with suspected renal artery stenosis?
Statement: We suggest performing renal artery ultrasound 
as a screening test first, followed by plain MR angiogra-
phy. When CT angiography and gadolinium-enhanced MR 
angiography are performed, the risk of contrast-induced 
nephropathy and nephrogenic systemic fibrosis must be 
considered carefully. When these tests do not lead to a diag-
nosis or when the indication of angioplasty is considered, 
we suggest performing renal artery angiography. (Level: C, 
Grade: 2)
CQ4: Is revascularization recommended for CKD with arte-
riosclerotic renal artery stenosis?
Statement: We do not suggest performing revascularization 
for CKD with arteriosclerotic renal artery stenosis in prin-
ciple due to the risk of complications, because it does not 
suppress the progression of renal dysfunction or decrease the 
risk of developing CVD. (Level: B, Grade: 2)
Chapter 6. Renal anemia
CQ1: What is the target Hb range in prescribing ESA for 
renal anemia in CKD patients?
Statement: We propose that the target Hb range for prescrib-
ing ESA to non-dialysis CKD patients is 11 g/dL or more 
and below 13 g/dL. In case of ESA hypo-responsiveness, 
determining the cause and correcting it are mandatory. 
Attention should be paid to avoiding over-dosage of ESA. 
For patients with a past history or complication of severe 
CVD or any other medical indications, one should consider 
reducing or terminating ESA use if Hb level exceeds 12 g/
dL (Level: B, Grade: 2).
CQ2: Is iron treatment recommended in anemic CKD 
patients with iron deficiency?
Statement: We propose iron treatment for anemic CKD 
patients with iron deficiency. (Level: B, Grade: 2)
Chapter 7. Management of chronic kidney 
disease‑mineral bone disease
CQ1: Is administration of phosphate binders recommended 
in non-dialysis CKD patients with hyperphosphatemia?
Statement: In non-dialysis CKD patients with hyperphos-
phatemia, the use of phosphate binders may be considered 
because phosphate binders have the possibility of reducing 
progression to mortality. (Level: C, Grade: 2)
CQ2: Is the administration of non-calcium-containing phos-
phate binders recommended for the treatment of hyperphos-
phatemia in non-dialysis CKD patients?
Statement: In non-dialysis CKD patients with hyperphos-
phatemia, the administration of non-calcium-containing 
phosphate binders may be considered because they are 
potentially more effective in preventing progression to mor-
tality and vascular calcification progression compared to 
calcium-containing phosphate binders (Level: C, Grade: 2).
CQ3: Is administration of active vitamin D recommended in 
non-dialysis CKD patients?
Statement: In non-dialysis CKD patients, administration of 
active vitamin D may be considered because it lowers PTH 
levels and may reduce proteinuria. However, active vitamin 
D can cause hypercalcemia and it is unknown whether this 
therapy decreases the risk of CKD progression, fracture, 
cardiovascular events, or mortality. Thus, we suggest thera-
peutic decisions be made on a case-by-case basis and active 
vitamin D be started with small doses. We also suggest that, 
in the case of hypercalcemia or worsening renal function, 
active vitamin D should be reduced or stopped promptly. 
(Level: C, Grade: 2)
CQ4: Is administration of anti-osteoporotic agents recom-
mended in non-dialysis CKD patients?
Statement: In non-dialysis CKD patients, administration of 
anti-osteoporotic agents, such as active vitamin D, bisphos-
phonates, selective estrogen receptor modulators (SERMs), 
teriparatide, and denosumab may be considered because 
these may reduce fracture risk. Special attention, however, 
needs to be paid during treatment in CKD patients, because, 
depending on the agent, the expected beneficial and adverse 
effects may differ from those observed in the general popula-
tion. (Level: D, Grade: 2)
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Chapter 8. Management of hyperuricemia 
and dyslipidemia
CQ1: Is uric acid-lowering therapy recommended in patients 
with CKD?
Statement: Uric acid-lowering therapy is suggested for 
patients with CKD and hyperuricemia, because it may 
potentially slow the progression of renal dysfunction and 
reduce urinary protein excretion. (Level: C, Grade: 2)
CQ2: Is lipid-lowering therapy recommended in patients 
with CKD?
Statement: Lipid-lowering therapy with statins or statins 
plus ezetimibe is recommended for patients with CKD and 
dyslipidemia, because it may potentially inhibit the devel-
opment and recurrence of CVD events, reduce urinary pro-
tein excretion, and slow progression of renal dysfunction 
(Level: B Grade: 2). Meanwhile, lipid-lowering therapy with 
fibrates also could be useful for preventing development and 
recurrence of CVD events in those patients; however, we 
should use them carefully because fibrates are contraindi-
cated or necessitate to be administered carefully in patients 
with moderate to severe renal dysfunction (Level: D, Grade: 
None).
Chapter 9. Management of metabolic 
syndrome
CQ1: Are obesity and metabolic syndrome risk factors of 
mortality, CVD, ESKD, and progression of CKD in patients 
with CKD?
Statement: Metabolic syndrome is potentially associated 
with mortality, CVD, ESKD, and progression of CKD in 
patients with CKD, although obesity is not obviously associ-
ated with these outcomes. (Level: C, Grade: None)
CQ2: Is exercise training recommended for CKD patients 
with obesity and/or metabolic syndrome?
Statement: We suggest that CKD patients with obesity and/
or metabolic syndrome follow an aerobic exercise training 
program, which is effective for weight loss and improve-
ment of peak oxygen consumption  (VO2 peak). Considering 
the clinical characteristics of each patient, the adequate load 
of aerobic exercise training should be estimated carefully. 
(Level: C, Grade: 2)
Chapter 10. Management of pregnancy
CQ1: Do CKD patients have higher risks of pregnancy com-
plications (i.e., for preeclampsia, premature birth, or fetal 
loss?
Statement: CKD patients have higher risks of pregnancy 
complications, such as preeclampsia, premature birth, or 
fetal loss, even in the CKD stage of G1. The risk is higher 
in patients with a higher CKD stage. (Level: C, Grade: 1)
CQ2: What antihypertensive agents are recommended for 
pregnant hypertensive CKD patients?
Statement: When antihypertensive medications are neces-
sary, not only in CKD patients, we can use methyldopa, 
labetalol, hydralazine, and slow-release nifedipine after the 
20th week of pregnancy. ACEIs and ARBs are contraindi-
cated in pregnant women. (Level: D, Grade: 2)
Chapter 11. Management of pediatric CKD
CQ1: Is urinary screening recommended for children at 
3 years of age and throughout the school age?
Statement: In pediatric populations, urinary screening at 
3 years of age and throughout school age is considered to 
contribute to the discovery of CKD at an early stage, thus, 
facilitating early management and improving the renal prog-
nosis. (Level: D, Grade: 2)
CQ2: Is CKD in pediatric patients a risk factor for CVD?
Statement: CKD in pediatric patients is a risk factor for 
CVD. (Level: C, Grade: None)
CQ3: Should low birth weight, preterm birth, and fetal 
growth retardation be treated as risk factors for CKD?
Statement: Since low birth weight, preterm birth, and fetal 
growth retardation are associated with future onset of CKD, 
it is recommended that they should be treated as risk factors. 
(Level: B, Grade: 1)
CQ4: Is exercise recommended for pediatric patients with 
CKD?
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Statement: We suggest that pediatric patients with CKD 
perform mild to moderate exercise to improve QOL, motor 
function, and respiratory function. (Level: C, Grade: 2)
CQ5: Is protein intake restriction recommended for pediatric 
patients with CKD?
Statement: As any preventive effects due to protein intake 
restriction against deterioration of renal function are still 
unclear, we suggest that this should not be implemented. 
(Level: B, Grade: 2)
CQ6: Is vaccination recommended for pediatric patients 
with CKD?
Statement: As pediatric patients with CKD are susceptible 
to infections that are likely to become severe, vaccination is 
recommended. (Level: C, Grade: 2)
CQ7: Is antihypertensive therapy recommended for pediatric 
CKD patients with hypertension?
Statement: For pediatric CKD patients with hypertension we 
suggest that antihypertensive therapy should be implemented 
along with lifestyle instruction and medication including RA 
inhibitors and calcium antagonists, on an individual basis 
and according to age. (Level: C, Grade: 2)
CQ8: Is management and therapy for CKD-MBD recom-
mended for pediatric patients with CKD?
Statement: As management of CKD-MBD for pediatric 
patients with CKD may improve bone lesions and cardio-
vascular function, we recommend that it should be imple-
mented. We suggest that the corrected serum levels of cal-
cium and phosphorus should be maintained within normal 
ranges in accordance with patient age. (Level: C, Grade: 2)
CQ9: Is administration of recombinant human growth hor-
mone (rhGH) recommended for pediatric patients with CKD 
showing growth stunting?
Statement: We suggest that rhGH administration should be 
considered for pediatric CKD patients with growth stunting 
as it can significantly increase the height of patients. (Level: 
A, Grade: 2)
CQ10: Is preemptive kidney transplantation (PEKT) recom-
mended for pediatric patients with CKD?
Statement: We suggested that preemptive kidney transplan-
tation should be considered for pediatric patients with CKD, 
as the likelihood of graft survival is higher than that after 
dialysis has been implemented. (Level: C, Grade: 2)
Chapter 12. Management of elderly CKD
Preamble: Renal replacement therapy (RRT) for elderly 
CKD patients aged more than 75 years
In elderly CKD patients aged more than 75 years, an 
improvement in life prognosis by RRT can be expected. It 
is important to consult with nephrologists/special medical 
institutions when choosing RRT. The selection should be 
based on appropriate decision-making through discussion 
with the patients and their families by comprehensive con-
sideration through the evaluation of renal function, medical 
history, multiple complications (CVD, malignant neoplasms, 
advanced dementia, severe frailty, and other), the patient’s 
social situation, and anticipated life expectancy. In addition, 
understanding and practice of an appropriate preservation 
therapy and palliative care are required when the patients 
decide to forgo hemodialysis.
CQ1: Is treatment for CKD-MBD recommended for the 
elderly (≥ 75 years) CKD patients?
Statement: In elderly patients (aged 75 years or more) with 
non-dialysis CKD, we suggest limiting dietary phosphate 
intake and/or using phosphate binders to maintain serum 
phosphate levels within the normal range. In this population, 
close monitoring for adverse effects is required to prevent 
malnutrition since the phosphate-lowering therapies may 
cause loss of appetite. (Level: C, Grade: 2)
In elderly non-dialysis CKD patients with secondary 
hyperparathyroidism, we suggest lowering parathyroid hor-
mone levels within the normal range by treating abnormali-
ties in serum phosphate and calcium levels before admin-
istering active vitamin D agents. Hypercalcemia must be 
avoided when using active vitamin D agents. (Level: C, 
Grade: 2)
CQ2: Can intervention in elderly CKD patients aged more 
than 75 years, prevent or control the progression of frailty, 
improve life prognosis, prolong induction of renal replace-
ment therapy?
Statement: In elderly CKD patients aged more than 75 years, 
frailty is one of the indicators of renal and life prognoses and 
incidence of renal replacement therapy. The effectiveness of 
intervention, nutrition therapy and exercise, in frail individu-
als is still not known. (Level: D, Grade: None)
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CQ3: Is lipid lowering therapy recommended for elderly 
CKD patients aged more than 75 years?
Statement: For elderly CKD patients aged 65–71 years, we 
propose that lipid lowering therapy (statin alone or a statin 
and ezetimibe combination) should be performed in elderly 
CKD patients aged 75 years or more since statins are effec-
tive for decreasing all -cause mortality and for primary or 
secondary prevention of CVD. (Level: C, Grade: 2)
CQ4: Is renal biopsy recommended for elderly people aged 
more than 75 years?
Statement: There is no basis for contraindications of renal 
biopsy in elderly individuals aged > 75 years. There is also 
the possibility that the appropriate treatment can be deter-
mined based on renal biopsy. With respect to implementa-
tion, renal biopsy on elderly people should be introduced to 
experienced nephrologists and specialized medical institu-
tions and their recommendations should be judged in con-
sideration of renal function prognosis/life prognosis. (Level: 
D, Grade: None)
CQ5: Could strict glycemic control (HbA1c < 7.0%) be rec-
ommended for CKD patients with DM aged more than 75 
years?
Statement: CKD patients with DM aged ≥ 75 years should 
be recognized as being at risk of severe hypoglycemia and 
falls with strict glycemic therapy. We suggest that the tar-
get for glycemic control for elderly CKD patients should be 
decided individually depending on the health condition (age, 
cognitive function, physical function, comorbidity, risk of 
hypoglycemia, and time to live). (Level: D, Grade: None)
CQ6: What is the optimal hemoglobin target range for ane-
mic elderly patients (≥75 years) CKD patients?
Statement: In anemic elderly patients (aged ≥ 75 years) with 
non-dialysis CKD, we suggest maintaining hemoglobin lev-
els within the target range of 11–13 g/dL using erythropoie-
tin-stimulating agents (ESAs) and/or iron supplementation. 
With respect to the mortality risk, the lower limit of the 
target range could be lowered to 9 g/dL. During the ESA 
therapy, clinical factors associated with resistance to ESAs 
should be removed to avoid use of high-dose ESAs. (Level: 
C, Grade: 2)
CQ7: Are there any drugs to be especially attentive on drug 
usage for elderly CKD patients aged more than 75 years in 
daily clinical practice?
Statement: Metabolic and excretion rates decline in elderly 
CKD patients aged more than 75 years, and attention must 
be paid to the control of the doses of RAS inhibitors, diuret-
ics, vitamin D, and other drugs, which are frequently admin-
istered. Moreover, to avoid polypharmacy, we propose to 
check the medication notebook. (Level: D, Grade: 2)
Chapter 13. Dialysis initiation
CQ1: When should CKD patients be introduced to nephrolo-
gists to appropriately prepare for dialysis initiation?
Statement: It has been reported that the nephrologist’s care 
of CKD patients before their dialysis initiation affects their 
selection of kidney transplantation or dialysis, increases the 
probability of success of operation of vascular access, and 
decreases early mortality after their dialysis initiation. When 
patients are at least CKD Stage G4, their consultation with 
nephrologists is proposed. (Level: C, Grade: 2)
CQ2: To prevent the progression of kidney injury and late 
dialysis initiation, is patient education by various medical 
staff members recommended for CKD patients at CKD stage 
G3b or later?
Statement: Because interdisciplinary team management 
including doctors and nurses may prolong dialysis initia-
tion, patient education by various medical staff members is 
recommended for CKD patients at CKD stage G3b or later. 
(Level: C, Grade: 2)
CQ3: Should we perform CVD screening at the initiation 
of dialysis?
Statement: There is no evidence to suggest that universal 
CVD screening is beneficial. However, as CKD is a well-
known risk factor for CVD, we suggest treatable CVD 
should be identified at least before the initiation of dialysis. 
(Level: D, Grade: 2)
Chapter 14. Kidney transplantation
CQ2: Is clinical follow-up recommended in post nephrec-
tomy living kidney donors?
Statement: We suggest donors undergo appropriate follow-
up similarly to CKD patients (Level: D, Grade: 2).
9Clinical and Experimental Nephrology (2019) 23:1–15 
1 3
CQ2: Is preemptive kidney transplantation (PEKT) 
recommended?
Statement: We suggest that PEKT is the renal replacement 
modality of choice for all suitable patients whenever a donor 
is available. (Level: D, Grade: 2)
CQ3: Is PEKT recommended for diabetic patients?
Statement: We suggest that PEKT is the renal replacement 
modality of choice for diabetic patients. (Level: D, Grade: 2)
Chapter 15. Management of drug treatment
CQ1: Is either an NSAID or acetaminophen recommended 
for patients with CKD suffering from pain?
Statement: Acetaminophen may be safer than NSAIDs for 
the short-term administration to patients with CKD. In par-
ticular, for elderly patients with decreased renal blood flow 
and GFR, the use of acetaminophen is proposed. However, 
even for acetaminophen, the safety of the long-term admin-
istration is not certain. (Level: D, Grade: 2)
CQ2: Is it recommended to treat patients with an oral spheri-
cal carbon adsorbent?
Statement: Although the therapeutic effect of an oral spheri-
cal carbon adsorbent on end-stage kidney disease (ESKD) 
or death in CKD patients is unclear, its treatment may be 
considered because there is a possibility of delaying CKD 
progression. (Level: C, Grade: 2)
CQ3: Is it recommended to reduce treatment with antivi-
ral drugs based on renal function in CKD patients suffering 
from herpesvirus infection?
Statement: When administering antiviral drugs to CKD 
patients suffering from herpes simplex/herpes zoster virus 
infection, we propose designing drug administration based 
on evaluation of the renal function. In many cases, it may be 
expected that there will be a decrease in the adverse event 
occurrence by a drug administration design based on renal 
function, but even if only the dose is adjusted, it is necessary 
to pay close attention to the occurrence of adverse events 
(Level: D, Grade: 2).
CQ4: How does CKD affect anticoagulant treatment of 
patients with non-valvular atrial fibrillation?
Statement: Anticoagulant treatment for non-valvular atrial 
fibrillation associated with CKD patients may reduce the 
risk of total death and thromboembolism. Meanwhile, given 
the potential increased risk of developing severe bleeding 
complications, a decision for administration is made in con-
sidering the balance between benefits and disadvantages in 
each case. (Level: D, Grade: 2)
CQ5: Does iodinated radiocontrast media worsen kidney 
function in people with CKD?
Statement: All individuals with GFR < 60 mL/min/1.73 m2 
(GFR categories G3a-5) are at risk for contrast media 
induced nephropathy (CIN) by the intravascular administra-
tion of iodinated radiocontrast media. This risk may increase 
especially in people with GFR < 45 mL/min/1.73 m2 (GFR 
categories G3b-5) or in cases in which large amount of iodi-
nated radiocontrast media was used. (Level: B, Grade: 1)
If the radiography with intravascular administration 
of iodinated radiocontrast media is required for patients 
with GFR < 60 mL/min/1.73 m2 (GFR categories G3a-5), 
informed consent, sufficient hydration with saline before, 
during, and after the procedure, and use of lowest possi-
ble iodinated radiocontrast media dose are recommended. 
(Level: D, Grade: 1)
CQ6: Is it recommended prescribers should take the kidney 
function into account when renally excreted drugs in people 
with CKD?
Statement: We recommend that prescribers take kidney 
function into account and modify administration methods 
and doses of renally excreted drugs in patients with CKD to 
reduce the possibility of adverse events. (Level: C, Grade: 1)
Chapter 16. Management of diabetic kidney 
disease
CQ1: Is the measurement of urine albumin recommended in 
a patient with diabetes mellitus?
Statement: Measurement of urine albumin is recommended 
in patients with diabetes mellitus since it is essential for the 
early diagnosis of diabetic nephropathy. (Level: B, Grade: 1)
CQ2: Is the administration of loop diuretics recommended 
for DKD patients with edema?
Statement: The administration of loop diuretics is recom-
mended for DKD patients with excess fluids. However, 
concomitant use with RAS inhibitors or NSAIDs, or 
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administration of excessive doses of loop diuretics may 
cause renal deterioration. Thus, careful follow-up observa-
tion is required throughout the administration period. (Level: 
D, Grade: 2)
CQ3: Is glycemic control with a target HbA1c level of less 
than 7.0% recommended in diabetic patients with chronic 
kidney disease?
Statement: Glycemic control aiming for an HbA1c level of 
less than 7.0% is recommended to prevent the progression 
of early stage diabetic nephropathy. There is not enough evi-
dence supporting the benefits of intensive glycemic control 
on renal outcomes in patients with diabetes with macroal-
buminuria or renal dysfunction. Caution is required for the 
risk of hypoglycemia when aiming for an HbA1c level of 
less than 7.0%. (Level: B, Grade: 1)
CQ4: Is a multifactorial intensive treatment recommended 
in patients with diabetes mellitus?
Statement: Multifactorial intensive treatment including a 
life-style modification and suitable management of risk fac-
tors such as blood glucose levels, BP and lipid profiles is 
recommended to inhibit the development and progression of 
diabetic vascular complications and to improve prognosis in 
patients with diabetes mellitus. (Level: B, Grade: 1)
Chapter 17: Management of intractable 
kidney disease
17-1: Management of IgA Nephropathy
CQ1: Is family history associated with disease onset or pro-
gression in IgA nephropathy?
Statement: There is no evidence that family history is associ-
ated with disease onset or progression in IgA nephropathy 
at present. (Level: D, Grade: None)
CQ2: Does hematuria (macroscopic or microscopic) influ-
ence renal outcome in patients with IgA nephropathy?
Statement: Currently, there is no sufficient evidence indicat-
ing hematuria influences renal outcome in patients with IgA 
nephropathy. (Level: C, Grade: None)
CQ3: Are RAS inhibitors recommended for use in patients 
with IgA nephropathy?
Statement: Since it has been reported that ACEIs or ARBs 
decrease the incidence of ESKD, the progression of renal 
dysfunction and reduce the amount of proteinuria in patients 
with IgA nephropathy, use of RAS inhibitors is recom-
mended. (Level: B, Grade: 1)
17-2: Management of Nephrotic Syndrome
CQ1: Are RAS inhibitors recommended for treatment of 
steroid-resistant or immunosuppressant-resistant primary 
nephrotic syndrome without hypertension in adults?
Statement: In adults with steroid-resistant or immunosup-
pressant-resistant primary nephrotic syndrome but without 
hypertension, we suggest using ACEIs or ARBs (not covered 
by medical insurance). (Level: C, Grade: 2)
CQ2: Is diagnosis by renal biopsy recommended for elderly 
patients with nephrotic syndrome?
Statement: We found no evidence to suggest/recommend 
renal biopsy in elderly patients with nephrotic syndrome 
and we propose consultation with kidney specialists and 
special medical institutions for specific indications. (Level: 
D, Grade: None)
CQ3: Is restriction of daily activity or exercise recom-
mended for the patients with nephrotic syndrome?
Statement: We found no evidence of benefit or harm from 
restricting daily activity or exercise for long-term outcomes 
in patients with nephrotic syndrome. (Level: D, Grade: 
None)
17-3: Management of Autosomal Dominant Polycystic Kid-
ney Disease (ADPKD)
CQ1: Should patients with ADPKD be screened for intrac-
ranial aneurysms?
Statement: There is no direct evidence to demonstrate that 
screening for intracranial aneurysms is beneficial for lower-
ing overall mortality or preventing rupture of aneurysms. 
Considering that prevalence of intracranial aneurysms in 
ADPKD patients is significantly higher than that in gen-
eral population, however, their screening using MRI is sug-
gested for ADPKD patients with a family history of intrac-
ranial aneurysms or subarachnoid hemorrhage. (Level: D, 
Grade: 2)
CQ 2: Is tolvaptan recommended for ADPKD patients?
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Statement: We recommend using tolvaptan for autosomal 
dominant ADPKD patients with a total kidney volume 
of ≥ 750 mL and with an estimated creatinine clearance 
of ≥ 60 mL/min. We also recommend using tolvaptan for 
later-stage ADPKD patients with an eGFR of 25–60 mL/
min/1.73 m2 to slow the increase in total kidney volume 
and the decline in kidney function. Safety and efficacy of 
tolvaptan in children have not been established yet. (Level: 
B, Grade: 1)
CQ3: Can RAS inhibitors be administered for hypertensive 
ADPKD patients?
Statement: We suggest that ACEIs or ARBs should be 
administered for hypertensive ADPKD patients from the 
viewpoint of suppressing the development of ESKD. (Level: 
C, Grade: 2)
17-4: Management of Rapidly Progressive Glomerulone-
phritis (RPGN)
CQ1: Is the use of “The guide for early diagnosis of rapidly 
progressive nephritic syndrome” recommended for detect-
ing RPGN in patients with urinary abnormalities and renal 
dysfunction?
Statement: We recommend the use of “The guide for early 
diagnosis of rapidly progressive nephritic syndrome” for 
detecting RPGN in patients with urinary abnormalities and 
renal dysfunction. (Level: D, Grade: 1)
CQ2: Is testing serum MPO-ANCA, PR3-ANCA and anti-
GBM antibody levels recommended for a differential diag-
nosis of RPGN in patients showing urinary abnormalities 
and worsening renal function within a few weeks or a few 
months?
Statement: Immediate testing of serum MPO-ANCA, PR3-
ANCA and anti-GBM antibody levels is recommended for 
a differential diagnosis of RPGN in patients showing uri-
nary abnormalities and worsening renal function. (Level: 
D, Grade: 1)
CQ3. Is starting glucocorticoids alone useful for the initial 
treatment of patients with ANCA-associated RPGN?
Statement: For the initial treatment of ANCA-associated 
RPGN, starting glucocorticoids alone is useful and is sug-
gested for ameliorating patient prognosis. (Level: D, Grade: 2)
However, we recommend that patients refractory to ini-
tial treatment or having organ-threatening or life-threat-
ening involvement be referred to, or managed in close 
collaboration with, an expert center and combined use of 
immunosuppressive therapy should be considered. (Level: 
D, Grade: 1)
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